Your Risk Management File Is Now a Commercial Asset

What was once a compliance deliverable is now shaping capital allocation, commercialization timing, and market viability.

What CEOs Should Really Take From This:

1. “State of the art” is an interpretive and strategic concept, not simply a technology benchmark.
   Regulators increasingly expect manufacturers to justify devices against accepted medical practice, alternative therapies, real-world clinical use, and evolving standards of care—not just technical innovation.

2. Regulatory unpredictability is becoming a business risk in itself.
   Inconsistent interpretations, shifting reviewer expectations, and expanding evidence demands are forcing medtech CEOs to treat regulatory strategy and risk management as executive-level commercial functions rather than back-office compliance activities

3. Risk management is no longer just a regulatory requirement—it directly impacts commercialization.
   Under the EU MDR, the risk management file influences market access, review timelines, clinical positioning, and even which geography companies choose to enter first.

---

There’s a moment in every medtech company’s lifecycle when leadership realizes the risk management file is no longer just a regulatory document.

It’s the business strategy.

Under the EU MDR, regulators and notified bodies increasingly use risk management as evidence that a manufacturer truly understands the clinical reality surrounding its device—not just the engineering. That shift is quietly reshaping commercialization timelines, clinical strategy, and even market selection.

The problem is that the European system itself does not operate with a single interpretive voice. The European Commission writes legislation. National competent authorities enforce it. Notified bodies assess conformity. Standards committees define technical expectations. Everyone is pursuing patient safety, but not always with the same interpretation.

That matters because MDR compliance increasingly depends on interpretation rather than straightforward regulatory clarity. The result is what manufacturers are experiencing now: inconsistent reviewer expectations, repeated requests for additional clinical justification, prolonged review cycles, and growing uncertainty around what qualifies as sufficient evidence.

Much of the confusion centers on the phrase “state of the art.”

Most executives hear that term and think “most advanced technology available.” ISO 14971:2019 does not. The standard defines state of the art as generally accepted good practice in medicine and technology and explicitly states that it does not necessarily mean the most technologically advanced solution.

That distinction changes the entire conversation.

Regulators are no longer simply asking whether a device is innovative. They are asking whether the manufacturer can justify its design choices, controls, usability profile, and clinical positioning relative to accepted medical and technological practice.

Complicating matters further, MDR often blends technical “state of the art” with clinical “standard of care” without clearly separating the two. And standard of care is not universal. It varies by geography, infrastructure, physician practice patterns, and patient population.

That is why risk management has evolved into a proxy for clinical credibility.

Manufacturers are increasingly expected to account for alternative therapies, evolving clinical guidelines, patient subgroups, contraindications, and real-world use conditions—not just competing devices. In practice, that means the comparison set may include surgery, pharmaceuticals, or entirely different approaches to care.

Meanwhile, reviewer turnover inside notified bodies is compounding the problem. Companies can cycle through multiple reviewers during a single submission, with each effectively resetting expectations. At some point, evidence generation stops being about clinical understanding and starts becoming an exercise in reducing reviewer uncertainty.

That becomes expensive fast.

The clearest signal that the landscape has changed is strategic: many companies now view the FDA pathway as more predictable than MDR certification. Europe was once the preferred first-market pathway. Increasingly, it is not.

For CEOs, this is no longer a regulatory operations issue. It is a capital allocation issue.

The companies navigating this environment best are not necessarily the ones with the largest regulatory teams. They are the ones treating risk management as an executive-level commercial function tied directly to market access, clinical positioning, and long-term growth.

Because under MDR, the risk management file is no longer documenting the business.

It’s increasingly determining whether the business gets to exist at all.